If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Bluescape Opportunities Acquisition (BOAC.U)
Pine Island Acquisition (PIPP.U)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Ajax I (AJAX.U)
Atlas Crest Investment Corp. (ACICU)
Absolute Software (ABST)
Upcoming IPO
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
OTR Acquisition (OTRAU)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Poseida Therapeutics, Inc. (PSTX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company dedicated to utilizing their proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. They have discovered and are developing a broad portfolio of product candidates in a variety of indications based on their core proprietary platforms, including their non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Their core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable them to engineer their wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. They are advancing a broad pipeline with a plan to have six CAR-T product candidates in the clinic in 2021 in both hematological and solid tumor oncology indications. Their most advanced product candidate, P-BCMA-101, is an autologous CAR-T which they are currently evaluating in a potentially registrational Phase 2 clinical trial, which they believe, if successfully completed, could support a submission seeking accelerated regulatory approval, and an expanded Phase 1 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma.
Eric M. Ostertag Mark J. Gergen
Employees Founded
149 2003


Address: 9390 Towne Centre Drive, Suite 200, San Diego, California 92121, US

Telephone: 858-779-3100

Web page:

IPO information

Expected Date 7/10/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $989
Revenues (MM) $0
Net Income (Loss) (MM) $-102.0


What do you think will happen with the PSTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 14
Expected offer amount (MM) $150
Realized offer amount(MM) $224
BofA Securities/ Piper Sandler/ William Blair

Sector: Healthcare

Tweets about $PSTX

Tweets volume:

RT volume:


Google Trends Stats